Apoptotic Signaling Pathways Induced by Nitric Oxide in Human Lymphoblastoid Cells Expressing Wild-Type or Mutant p53

Biological Engineering Division and Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, USA.
Cancer Research (Impact Factor: 9.28). 06/2004; 64(9):3022-9. DOI: 10.1158/0008-5472.CAN-03-1880
Source: PubMed

ABSTRACT Loss of p53 function by inactivating mutations results in abrogation of NO*induced apoptosis in human lymphoblastoid cells. Here we report characterization of apoptotic signaling pathways activated by NO* in these cells by cDNA microarray expression and immunoblotting. A p53-mediated transcriptional response to NO* was observed in p53-wild-type TK6, but not in closely related p53-mutant WTK1, cells. Several previously characterized p53 target genes were up-regulated transcriptionally in TK6 cells, including phosphatase PPM1D (WIP1), oxidoreductase homolog PIG3, death receptor TNFRSF6 (Fas/CD95), and BH3-only proteins BBC3 (PUMA) and PMAIP1 (NOXA). NO* also modulated levels of several gene products in the mitochondria-dependent and death-receptor-mediated apoptotic pathways. Inhibitors of apoptosis proteins X-chromosome-linked inhibitor of apoptosis, cellular inhibitor of apoptosis protein-1, and survivin were significantly down-regulated in TK6 cells, but not in WTK1 cells. Smac release from mitochondria was induced in both cell types, but release of apoptosis-inducing factor and endonuclease G was detected only in TK6 cells. Fas/CD95 was increased, and levels of the antiapoptotic proteins Bcl-2 and Bcl-x/L were reduced in TK6 cells. Activation of procaspases 3, 8, 9, and 10, as well as Bid and poly(ADP-ribose) polymerase cleavage, were observed only in TK6 cells. NO* treatment did not alter levels of death receptors 4 and 5, Fas-associated death domain or proapoptotic Bax and Bak proteins in either cell line. Collectively, these data show that NO* exposure activated a complex network of responses leading to p53-dependent apoptosis via both mitochondrial and Fas receptor pathways, which were abrogated in the presence of mutant p53.

Download full-text


Available from: Ana I Robles, Aug 17, 2015
  • Source
    • "A prior study of human lymphoblastoid cells reported that a line expressing wild type p53 demonstrated reduction of XIAP during nitric oxide (NO) induced apoptosis, but in a similar cell line expressing only mutant p53 no change in XIAP level was observed (Li et al. 2002). Further mRNA expression analysis from these cell lines revealed downregulation of XIAP and additional IAPs (cIAP1 and survivin) in p53 expressing cells, but closely related p53 mutant cells were resistant to NO-induced reduction of XIAP (Li et al. 2004). In agreement with these previous reports, we observed that p53 deficient primary cortical cultures possess increased "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cultured cortical neurons exposed to the Human Immunodeficiency Virus gp120 coat protein undergo apoptosis involving activation of both caspase-8 and caspase-9. Additionally, gp120-mediated neuronal apoptosis requires the pro-apoptotic transcription factor p53. As caspase-8-induced apoptosis does not typically require p53, we examined the possibility of a novel role for p53 in caspase-8 activation initiated by gp120. We observed that gp120 treatment of cultured cortical neurons induced caspase-8 activity and Bid cleavage independently of p53, but induction of caspase-3 enzymatic activity required p53 expression. These findings suggested the possibility that p53 down-regulates a caspase-3 inhibitor. We observed high-level expression of the caspase-3/9 inhibitor X-linked inhibitor of apoptosis protein (XIAP) in cultured cortical neurons. Adenoviral expression of p53 or induction of endogenous p53 by camptothecin treatment reduced XIAP protein in neurons. Infection with a p53 expressing adenovirus increased expression of the mRNA for Omi/HtrA2, a protease that cleaves and inactivates XIAP. These findings suggest that p53 regulates neuronal apoptosis, in part, by suppressing the anti-apoptotic protein XIAP via transcriptional activation of Omi/HtrA2.
    Journal of Neurochemistry 09/2007; 102(4):1206-19. DOI:10.1111/j.1471-4159.2007.04609.x · 4.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nitric oxide (NO) is a dynamic and bioreactive molecule that can both participate in and inhibit the genesis of disease. Its ability to have an impact on a wide range of physiological events stems from its capacity to reversibly alter the expression of specific genes and the activities of a wide range of proteins and signaling pathways. Yet, NO* remains an enigmatic molecule. Recently developed technologies, including gene-chips, two-dimensional electrophoresis, RNA interference, matrix-assisted laser desorption ionization (MALDI)-TOF (time-of-flight) mass spectrometry, and protein arrays will allow us to better understand how NO* and associated reactive nitrogen species (RNS) regulate both physiology and disease states, toward the development of treatments using NO* synthase inhibitors or NO* donors.
    Methods in Enzymology 02/2005; 396:326-40. DOI:10.1016/S0076-6879(05)96027-8 · 2.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nitric oxide (NO) is an important bioregulatory molecule in the nervous, immune and cardiovascular systems. NO participates in the regulation of the daily activities of cells as well as in cytotoxic events. It possesses a controversial effect on cell viability by acting both as a protection against apoptogenic stimuli, or by inducing apoptosis when produced at elevated concentrations. The mechanisms of NO in regulating these biological functions can be either through cyclic guanylate cyclase (cGMP)-dependent or cGMP-independent pathways. The purpose of this review is to highlight the implication of NO in cell signalling, synaptic transmission, and cell death. We focus also on the protective role as well as the toxicity of NO. Finally, the adverse effects of inhaled nitric oxide are also depicted in this review.
    Toxicology 04/2005; 208(2):177-92. DOI:10.1016/j.tox.2004.11.032 · 3.75 Impact Factor
Show more